Lee’s Pharmaceutical Holdings Limited (HK:0950) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lee’s Pharmaceutical Holdings Limited has announced the initiation of a Phase I clinical trial for AU409, a novel oral treatment for advanced liver cancer developed by Auransa and manufactured by the Group’s subsidiary. The trial, which marks the first human study of AU409 in Asia, is focused on patients who have not responded to standard treatments and aims to establish the drug’s safety, dosage, and preliminary efficacy. Results from the trial, conducted at Queen Mary Hospital in Hong Kong, are anticipated to influence new drug registration in China.
For further insights into HK:0950 stock, check out TipRanks’ Stock Analysis page.